Cases & Deals

  • Home
  • Practices
  • Cellectis completes acquisition of Cellartis and €50 million private placement and issues free share purchase warrants to existing shareholders

Share

Cellectis completes acquisition of Cellartis and €50 million private placement and issues free share purchase warrants to existing shareholders

November 2011

Client(s) Cellectis SA

Jones Day advised Cellectis SA, a world leader in genome engineering listed on the Alternext market of NYSE Euronext Paris, in connection with the €33.8 million acquisition of Cellartis, the European stem cell leader, in conjunction with the €50 million private placement of convertible bonds evenly subscribed by the Fonds Stratégique d'Investissement (FSI) and Pierre Bastid and the issuance of free share purchase warrants to existing shareholders.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.